KRAS G12C Mutation: An Emerging Actionable Biomarker for NSCLC Sponsored by Amgen®
Give Us Your Feedback
Impact of a Digital Diabetes Prevention Program on Risk factors for Chronic Disease in a Workforce Cohort
High-Throughput Mass Spectrometry Assay for Quantifying β-Amyloid 40 and 42 in Cerebrospinal Fluid.
Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules